Health
Trial testing anti-coronavirus hIVIG plus remdesivir in COVID-19 patients – European Pharmaceutical Review
The ITAC trial will establish if hyperimmune intravenous immunoglobulin (hIVIG) plus remdesivir can improve COVID-19 patient outcomes.
Posted: 9 October 2020 | Hannah Balfour (European Pharmaceutical Review) | No comments yet
The ITAC trial will establish if adding hyperimmune intravenous immunoglobulin (hIVIG) to a remdesivir regimen can improve hospitalised COVID-19 patient outcomes.
A Phase III trial to evaluate the safety, tolerability and efficacy of a combination of the antiviral remdesivir and a highly concentrated solution of SARS-CoV-2 neutralising antibodies in hospitalised adult COVID-19 patients has begun.
The tr…
Continue Reading
